alexa High-Dose-Rate Brachytherapy for Favorable-Risk Adenocarcinoma of the Prostate

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

High-Dose-Rate Brachytherapy for Favorable-Risk Adenocarcinoma of the Prostate

To evaluate the acute genitourinary (GU) and gastrointestinal (GI) toxicities, health-related quality of life (HRQOL) factors, biochemical control rates, and technical feasibility of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer delivered in a single fraction.

 

Citation: Dahlbeck S, C.Hansen C, deRiese W, Kagan AR, Torres C, et al. (2015) A prospective Pilot Study of Single 19 Gy Fraction High-Dose-Rate Brachytherapy for Favorable-Risk Adenocarcinoma of the Prostate. J Nucl Med Radiat Ther 6:215. doi: 10.4172/2155-9619.1000215
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger